An intranasal formulation of AstraZeneca's widely-used COVID-19 vaccine Vaxzevria has failed at the first hurdle, after results from a phase 1 trial found it was unable to stimulate a strong ...

The U.S. FDA has given the green light for AstraZeneca's FluMist nasal spray vaccine to be self-administered or administered ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser.

Here intranasal vaccines may achieve what OPV ... adenoviruses naturally infect mucosal tissue. For e.g. the AstraZeneca IN vaccine trials that are currently ongoing, the challenge would seem ...

Nasal vaccines could still be a powerful weapon in the fight against Covid-19 despite “disappointing” recent trial results for an AstraZeneca spray, experts say. By entering the body the same ...

In AstraZeneca’s trial, 100% of adults were able to administer a full dose to themselves. The ease of giving the nasal spray ...

who formed the University of Oxford team that developed the vaccine marketed by AstraZeneca, pointed out to the UK’s Commons Science and Technology Committee that there is already a nasal ...

On April 30, AstraZeneca admitted that the vaccine, sold under the name Vaxzevria, can cause fatal blood clots and low platelet counts, also known as thrombosis syndrome with thrombocytopenia ...

AstraZeneca, the pharmaceutical giant ... with maximum cases reported from the US. iNCOVACC intranasal COVID vaccine, made by Bharat Biotech has been priced at Rs 800 at private hospitals and ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

“At the current time, the use of the Pfizer vaccine is preferred over the AstraZeneca vaccine in adults aged less than 50 years who have not already received a first dose of AstraZeneca vaccin ...

AstraZeneca made headlines on Tuesday as it initiated the global withdrawal of its COVID-19 vaccine. This decision comes weeks after the pharmaceutical giant acknowledged the vaccine's potential ...